Specification of Tirzepatide
| CAS No. | 2023788-19-2 | Molecular Weight | 4813.45 |
| Molecular Formula | C225H348N48O68 | Storage Condition | 2-8℃ |
Appearance: white freeze-dried powder
Product Description
Tirzepatide is an innovative biologic that was approved by the US FDA in May 2022. The drug is a dual agonist that acts on both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, demonstrating unique potential in the treatment of diabetes. The molecular structure of Tirzepatide contains 39 amino acids, including tyrosine, α-aminoisobutyric acid, glutamic acid, and other components, which together constitute its unique pharmacological properties.
Product action mechanism
Tirzepatide exerts its pleiotropic effect by activating GIP and GLP-1 receptors. Specifically, it can enhance insulin secretion and inhibit glucagon secretion, thus effectively reducing blood sugar levels. In addition, Tirzepatide slows the emptying of the stomach and increases the feeling of fullness, which in turn helps control appetite and weight. This dual mechanism of action gives Tirzepatide a wide application prospect in the field of diabetes and weight management.
Clinical application and effect of the product
Tirzepatide has shown remarkable curative effects in clinical applications. Multiple clinical trials have shown that Tirzepatide is superior to other traditional drugs in improving blood sugar control in patients with type 2 diabetes, while also having a good weight loss effect. In addition, Tirzepatide is also being investigated for the treatment of other indications such as non-alcoholic steatohepatitis (NASH) and heart failure, showing its potential for broad application.
Product side effects and precautions
Although Tirzepatide has shown excellent performance in clinical applications, potential side effects should be noted during its use. Common side effects include gastrointestinal discomfort such as nausea, diarrhea, vomiting, constipation, indigestion, and stomach pain, most of which are mild to moderate. Therefore, when using Tirzepatide, the patient’s condition should be closely monitored and the dose should be adjusted as needed. At the same time, Tirzepatide should be contraindicated in patients with the following conditions: allergy to Tirzepatide or its components; serious heart disease, gastrointestinal disease, pancreatitis, or thyroid problems; and pregnant and lactating women.
In conclusion, Tirzepatide, as an innovative dual receptor agonist, shows great potential in the field of diabetes and weight management. However, it is also necessary to pay attention to its potential side effects and precautions during use to ensure patient safety and efficacy. With the deepening of clinical research and the accumulation of experience, it is believed that Tirzepatide will bring good news to more patients.
English
Nederland
